Centrally mediated cardiovascular and EEG responses to bradykinin and eledoisin.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects*; D001920:Bradykinin / Q000008:administration & dosage*; D001921:Brain / Q000187:drug effects*; D002339:Carotid Arteries; D002415:Cats; D002552:Cerebral Ventricles; D004569:Electroencephalography; D004600:Eledoisin / Q000008:administration & dosage*; D005260:Female; D006321:Heart / Q000187:drug effects; D006584:Hexamethonium Compounds / Q000494:pharmacology; D007269:Injections, Intra-Arterial; D008297:Male; D010646:Phentolamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D011984:Sensory Receptor Cells / Q000187:drug effects; D014655:Vascular Resistance / Q000187:drug effects
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D006584:Hexamethonium Compounds; D004600:Eledoisin; D001285:Atropine; D011433:Propranolol; D001920:Bradykinin; D010646:Phentolamine